Right to Try Clarification Act

The Right to Try Clarification Act, also known as Bill 118 hr 1825, is a piece of legislation that aims to clarify and expand upon the existing Right to Try law. The Right to Try law was originally passed in 2018 and allows terminally ill patients to access experimental treatments that have not yet been fully approved by the Food and Drug Administration (FDA).

The Right to Try Clarification Act seeks to address some of the ambiguities and limitations of the original law. One key provision of the bill is to clarify that manufacturers of experimental treatments are not required to report adverse events to the FDA unless they are already required to do so under existing regulations. This is intended to reduce the burden on manufacturers and streamline the process of providing access to experimental treatments for patients.

Additionally, the bill includes provisions to protect healthcare providers who prescribe experimental treatments in good faith from liability, as well as provisions to ensure that patients are fully informed about the risks and benefits of the treatments they are receiving. Overall, the Right to Try Clarification Act aims to make it easier for terminally ill patients to access potentially life-saving experimental treatments while also providing important protections for patients, healthcare providers, and manufacturers.